EYPT
Eyepoint Pharmaceuticals Inc
3.60$
-0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | +1,347.2% | -10.7% | +0.0% | +56.7% | -42.8% | -29.7% | +9.6% | +9.5% | -56.3% | -21.1% | +39.5% | +42.8% | +0.0% | -42.3% | +0.0% | +283.7% | +1.8% | +25.7% | +187.2% | -31.5% | +96.9% | +17.8% | -13.0% | |
| – | – | – | +1,102.1% | +0.0% | +0.0% | -41.7% | +187.0% | -38.3% | +74.5% | +33.3% | -37.1% | -21.9% | +55.2% | +54.3% | +0.0% | -40.5% | +0.0% | +125.0% | +4.5% | +51.3% | +276.7% | -27.3% | +99.5% | +11.2% | -14.3% | |
| – | – | – | +2,647.9% | -55.1% | +0.0% | -56.6% | +267.3% | -36.9% | +57.5% | -16.8% | -64.2% | +49.2% | +122.3% | +24.7% | -19.9% | +10.4% | +0.0% | +129.5% | -42.7% | +102.2% | +297.7% | -46.5% | +194.1% | -64.6% | +2.1% | |
| – | – | – | -55.1% | +0.0% | +0.0% | -56.6% | +267.3% | -36.9% | +78.3% | +37.4% | -39.6% | -29.5% | +77.9% | +56.1% | +1.6% | -41.7% | +0.0% | +129.5% | -42.7% | +102.2% | +371.1% | -31.7% | +129.0% | +12.0% | -17.5% | |
| – | – | – | +127.7% | +0.0% | +0.0% | +201.0% | -9.5% | -39.7% | +25.5% | -24.1% | +14.7% | -38.3% | -13.4% | +20.3% | -21.5% | -48.6% | +0.0% | +40.6% | +3,120.4% | -16.8% | +94.2% | -15.5% | -94.8% | -24.6% | +7.2% | |
| – | – | – | – | – | – | +0.0% | +9.3% | – | – | – | – | – | – | – | – | – | – | – | – | +149.6% | -32.2% | -20.2% | +35.3% | -41.0% | -21.3% | |
| – | – | – | +72.0% | +435.2% | -6.5% | -78.0% | -7.6% | -86.0% | -34.8% | +186.0% | +172.4% | -46.6% | +65.9% | +13.8% | -14.2% | +7.9% | -19.2% | +13.8% | +24.0% | +76.5% | +257.5% | -39.6% | – | – | – | |
| – | – | – | – | +5,402.9% | +0.0% | -95.9% | +0.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +975.6% | +26.2% | +0.0% | +1.3% | -21.0% | -29.2% | +3.2% | -17.1% | -9.7% | -80.4% | -18.8% | -19.4% | -30.4% | -42.8% | -67.0% | +8,514.8% | -11.8% | -8.9% | -9.8% | – | – | – | – | |
| – | – | – | +128.9% | +15.5% | +0.0% | +1,919.2% | -18.1% | -32.2% | -42.8% | -2.9% | -28.1% | +22.8% | -9.4% | +16.2% | +19.3% | -50.3% | +0.0% | +1,023.1% | +7.8% | +13.2% | +7.9% | +6.3% | +5.8% | -7.8% | -29.4% | |
| – | – | – | +164.3% | +0.0% | +0.0% | +1,436.3% | -27.7% | -24.1% | -77.6% | +71.5% | -36.8% | +3.9% | -35.6% | +57.5% | +52.1% | +3.9% | +0.0% | +309.5% | -46.8% | +29.2% | +58.9% | +46.0% | +83.2% | -22.5% | -24.5% | |
| – | – | – | – | – | – | -99.8% | -62.4% | +25.3% | -30.6% | -25.4% | +14.2% | – | – | – | – | – | – | -99.8% | +1,503.3% | +1,655.7% | -90.7% | +1,313.6% | -94.9% | +121.5% | +62.1% | |
| – | – | – | +89.7% | -2.5% | +0.0% | +477.1% | -69.5% | -85.8% | +3.5% | -15.2% | +20.1% | +70.3% | -30.8% | +60.3% | +83.2% | -25.5% | +0.0% | +555.8% | -37.1% | +14.8% | +53.5% | -19.9% | +9.9% | +80.2% | -10.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +1.8% | +168.0% | -19.6% | -3.7% | -19.8% | – | – | – | |
| – | – | – | +525.3% | +137.2% | +0.0% | +9.0% | -54.6% | -27.6% | +51.6% | +13.3% | -63.6% | -43.5% | +93.8% | +56.6% | -10.6% | -36.1% | +0.0% | -12.4% | -28.7% | +122.6% | +894.4% | -47.7% | +176.4% | +26.4% | -9.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -66.6% | -10.7% | -57.7% | +0.0% | +44.8% | +46.8% | +64.6% | +0.5% | +3.5% | +3.1% | +6.7% | +10.8% | +19.1% | +11.4% | +3.4% | +11.8% | +30.8% | +125.6% | +23.1% | +124.0% | +29.8% | +4.3% | +44.7% | +30.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.